1
|
Epstein RJ. Has discovery-based cancer research been a bust? Clin Transl Oncol 2013; 15:865-70. [PMID: 24002944 DOI: 10.1007/s12094-013-1071-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2013] [Accepted: 06/18/2013] [Indexed: 12/11/2022]
Abstract
The completion of the human genome sequence sparked optimism about prospects for new anticancer drug development, but clinical progress over the last decade has proven slower than expected. Here it is proposed that unrealistically high expectations of first-generation discovery-based diagnostics have contributed to this problem. Hypothesis-based single-molecule tests (e.g., mutation screening of KRAS, EGFR, BRAF or KIT genes) continue to change clinical practice incrementally, whereas first-generation multiplex assays--such as gene expression profiling and proteomics--have identified few high-impact therapeutic targets despite numerous correlations with prognosis. To move forward, second-generation multiplex diagnostics should be based not on statistical patterns/associations alone, but on clinically interpretable ('high-signal-to-noise') data such as change-of-function mutations, gene amplifications, recurrent chromosomal anomalies, and abnormal phosphorylation profiles of ERK or mTOR signaling cascades.
Collapse
Affiliation(s)
- R J Epstein
- Department of Oncology, Clinical Cancer Informatics & Research Centre, The Kinghorn Cancer Centre, Sydney, Australia,
| |
Collapse
|
2
|
Pyrvinium targets the unfolded protein response to hypoglycemia and its anti-tumor activity is enhanced by combination therapy. PLoS One 2008; 3:e3951. [PMID: 19079611 PMCID: PMC2597738 DOI: 10.1371/journal.pone.0003951] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2008] [Accepted: 11/13/2008] [Indexed: 12/11/2022] Open
Abstract
We identified pyrvinium pamoate, an old anthelminthic medicine, which preferentially inhibits anchorage-independent growth of cancer cells over anchorage-dependent growth (∼10 fold). It was also reported by others to have anti-tumor activity in vivo and selective toxicity against cancer cells under glucose starvation in vitro, but with unknown mechanism. Here, we provide evidence that pyrvinium suppresses the transcriptional activation of GRP78 and GRP94 induced by glucose deprivation or 2-deoxyglucose (2DG, a glycolysis inhibitor), but not by tunicamycin or A23187. Other UPR pathways induced by glucose starvation, e.g. XBP-1, ATF4, were also found suppressed by pyrvinium. Constitutive expression of GRP78 via transgene partially protected cells from pyrvinium induced cell death under glucose starvation, suggesting that suppression of the UPR is involved in pyrvinium mediated cytotoxicity under glucose starvation. Xenograft experiments showed rather marginal overall anti-tumor activity for pyrvinium as a monotherapy. However, the combination of pyrvinium and Doxorubicin demonstrated significantly enhanced efficacy in vivo, supporting a mechanistic treatment concept based on tumor hypoglycemia and UPR.
Collapse
|
3
|
Selective anticancer strategies via intervention of the death pathways relevant to cell transformation. Cell Death Differ 2008; 15:1197-210. [DOI: 10.1038/cdd.2008.48] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
|
4
|
Müller-Hartmann H, Faust N, Kazinski M, Kretzschmar T. High-throughput transfection and engineering of primary cells and cultured cell lines – an invaluable tool for research as well as drug development. Expert Opin Drug Discov 2007; 2:1453-65. [DOI: 10.1517/17460441.2.11.1453] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
5
|
Li QX, Tan P, Ke N, Wong-Staal F. Ribozyme technology for cancer gene target identification and validation. Adv Cancer Res 2007; 96:103-43. [PMID: 17161678 DOI: 10.1016/s0065-230x(06)96005-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Ribozymes are naturally occurring RNAs with catalytic activities including cis- or trans- cleavage of RNA at predefined sequence sites. This activity has been exploited for specific gene inactivation in cells during the last two decades, and ribozymes have been important functional genomics tools, especially in the pre-RNAi era. It has also been broadly applied in drug target identification and validation in pharmaceutical R&D. This chapter covers many application principles and case studies of ribozyme technology in the areas of cancer research. We also described RNAi applications in some of the same studies for comparison. Although RNAi may be more effective than ribozymes in many respects, they are nonetheless built on many of the same principles.
Collapse
Affiliation(s)
- Qi-Xiang Li
- Immusol, Inc., San Diego, California 92121, USA
| | | | | | | |
Collapse
|
6
|
Leiser SF, Salmon AB, Miller RA. Correlated resistance to glucose deprivation and cytotoxic agents in fibroblast cell lines from long-lived pituitary dwarf mice. Mech Ageing Dev 2006; 127:821-9. [PMID: 16979221 DOI: 10.1016/j.mad.2006.08.003] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2006] [Revised: 07/06/2006] [Accepted: 08/09/2006] [Indexed: 11/16/2022]
Abstract
Fibroblast cell lines derived from the skin of young adult mice of the long-lived Snell dwarf mutant mouse stock have been shown to be resistant to the cytotoxic effects of multiple agents, including hydrogen peroxide, cadmium, heat, ultraviolet light, and the carcinogen methyl methanesulfonate. Snell dwarf fibroblasts are here reported to differ from control cell lines in two other respects: they are relatively resistant to the metabolic inhibition induced by low glucose concentrations, and also resistant to the effects of the mitochondrial poison rotenone, a blocker of Complex I of the electron transport chain. Furthermore, analysis of cell lines derived from a group of genetically heterogeneous mice established that cell lines resistant to peroxide-induced cytotoxicity were also relatively resistant to death induced by paraquat, cadmium, and ultraviolet light. Resistance to the metabolic effects of low glucose medium was associated with resistance to peroxide and cadmium in cells from heterogeneous mice and Snell dwarf mice, though unexpectedly not associated with resistance to the lethal effects of paraquat or UV light. Further analysis of the basis for metabolic abnormalities in these cell lines may provide insights into the cause of stress resistance in dwarf-derived cultures and to the longevity and disease-resistance of these long-lived mutant mice.
Collapse
Affiliation(s)
- Scott F Leiser
- Cellular and Molecular Biology Graduate Program, University of Michigan School of Medicine, Ann Arbor, MI 48109-2200, USA
| | | | | |
Collapse
|
7
|
Yang JP, Fan W, Rogers C, Chatterton JE, Bliesath J, Liu G, Ke N, Wang CY, Rhoades K, Wong-Staal F, Li QX. A novel RNAi library based on partially randomized consensus sequences of nuclear receptors: Identifying the receptors involved in amyloid β degradation. Genomics 2006; 88:282-92. [PMID: 16631344 DOI: 10.1016/j.ygeno.2006.03.010] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2005] [Revised: 03/13/2006] [Accepted: 03/16/2006] [Indexed: 10/24/2022]
Abstract
Combinatorial gene inactivation using an RNAi library is a powerful approach to discovering novel functional genes. However, generation of a comprehensive RNAi library remains technically challenging. In this report, we describe a simple and novel approach to designing gene-family-specific RNAi libraries by targeting conserved motifs using degenerate oligonucleotides. We created an siRNA library in the pHUMU vector using partially randomized sequences targeting the consensus region in the ZnF_C4 signature motif of the nuclear hormone receptors and thus against the entire receptor superfamily. For proof of principle, we adapted a reporter assay to screen this library for receptors that might be involved in reducing amyloid beta peptide accumulation. We modified a previously described luciferase reporter assay to measure the amyloid beta precursor cleavages occurring only between beta- and gamma-secretase cleavage sites, thus excluding the major gamma-secretase activities that could generate neurotoxic Abeta peptides. Our screen using this assay identified siRNA vectors that specifically increase the Abeta40/42 cleavage and pointed to a potential receptor target, ROR-gamma. SiRNAs targeting other regions of ROR-gamma not only confirmed the observed reporter activity but also reduced the level of the toxic Abeta peptides. The results demonstrated a general principle for the creation and application of this RNAi library approach for functional gene discovery within a predefined protein family. The discovered negative effect of ROR-gamma on the degradation of the toxic Abeta peptides may also provide a potential drug target or targetable pathway for intervention of Alzheimer disease.
Collapse
Affiliation(s)
- Jian-Ping Yang
- Immusol, Inc., 10790 Roselle Street, San Diego, CA 92121, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Yu DH, Macdonald J, Josephs S, Liu Q, Nguy V, Tor Y, Wong-Staal F, Li QX. MDDD, a 4,9-diazapyrenium derivative, is selectively toxic to glioma cells by inducing growth arrest at G0/G1 independently of p53. Invest New Drugs 2006; 24:489-98. [PMID: 16633716 DOI: 10.1007/s10637-006-7590-1] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
4-Methyl-2,7-diamino-5,10-diphenyl-4,9-diaz-apyrenium chloride (MDDD), a stable and water soluble nucleic acid-intercalating agent, was shown to be toxic to cancer cells with IC50 around 10 microM. IC(50) We tested MDDD for its potential antitumor activities and found it inhibited cancer cell growth with IC(50) in the micromolar range for the majority of cancer cells tested, with the exception of glioma cells, for which the IC(50) is in the submicromolar range. This unique selectivity of MDDD to glioma cells can potentially be exploited for anti-glioma therapeutics. Although the underlying mechanisms for the apparent glioma specificity remain to be elucidated, our analysis indicates that MDDD significantly reduces cell clonogenicity and blockes cell proliferation at the G1 phase. MDDD treatment also triggers induction of p53 and p21 at the protein levels, suggesting the activation of DNA damage response. However, MDDD mediated growth inhibition does not require the p53 pathway since p53+/- isogenic cell pairs display the same sensitivity. These properties of MDDD favor its candidacy for evaluation as a new anti-tumor agent, particularly for glioma.
Collapse
Affiliation(s)
- De-Hua Yu
- Immusol Inc., 10790 Roselle Street, San Diego, CA 92121, USA
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Yu DH, Fan W, Liu G, Nguy V, Chatterton JE, Long S, Ke N, Meyhack B, Bruengger A, Brachat A, Wong-Staal F, Li QX. PHTS, a novel putative tumor suppressor, is involved in the transformation reversion of HeLaHF cells independently of the p53 pathway. Exp Cell Res 2006; 312:865-76. [PMID: 16413018 DOI: 10.1016/j.yexcr.2005.12.006] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2005] [Revised: 10/30/2005] [Accepted: 12/01/2005] [Indexed: 10/25/2022]
Abstract
HeLaHF is a non-transformed revertant of HeLa cells, likely resulting from the activation of a putative tumor suppressor(s). p53 protein was stabilized in this revertant and reactivated for certain transactivation functions. Although p53 stabilization has not conclusively been linked to the reversion, it is clear that the genes in p53 pathway are involved. The present study confirms the direct role of p53 in HeLaHF reversion by demonstrating that RNAi-mediated p53 silencing partially restores anchorage-independent growth potential of the revertant through the suppression of anoikis. In addition, we identified a novel gene, named PHTS, with putative tumor suppressor properties, and showed that this gene is also involved in HeLaHF reversion independently of the p53 pathway. Expression profiling revealed that PHTS is one of the genes that is up-regulated in HeLaHF but not in HeLa. It encodes a putative protein with CD59-like domains. RNAi-mediated PHTS silencing resulted in the partial restoration of transformation (anchorage-independent growth) in HeLaHF cells, similar to that of p53 gene silencing, implying its tumor suppressor effect. However, the observed increased transformation potential by PHTS silencing appears to be due to an increased anchorage-independent proliferation rate rather than suppression of anoikis, unlike the effect of p53 silencing. p53 silencing did not affect PHTS gene expression, and vice versa, suggesting PHTS may function in a new and p53-independent tumor suppressor pathway. Furthermore, over-expression of PHTS in different cancer cell lines, in addition to HeLa, reduces cell growth likely via induced apoptosis, confirming the broad PHTS tumor suppressor properties.
Collapse
Affiliation(s)
- De-Hua Yu
- Immusol, Inc. 10790 Roselle Street, San Diego, CA 92121, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Liu G, Grifman M, Keily B, Chatterton JE, Staal FW, Li QX. Mineralocorticoid receptor is involved in the regulation of genes responsible for hepatic glucose production. Biochem Biophys Res Commun 2006; 342:1291-6. [PMID: 16516149 DOI: 10.1016/j.bbrc.2006.02.065] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2006] [Accepted: 02/06/2006] [Indexed: 12/28/2022]
Abstract
The mineralocorticoid receptor (MR) is expressed in kidney and plays a central role in the control of sodium, homeostatic fluid, and blood pressure. It has also been implicated in other functions in cardiovascular system, central nervous system, and adipose tissue. This study revealed a novel role of MR in the gene regulation related to hepatic glucose production. RNAi-mediated MR silencing led to a decrease in the expression of glucose-6-phosphatase (G6Pase), phosphoenolpyruvate carboxykinase, and fructose-1,6-bisphosphatase 1, the enzymes known to be involved in glucose production in liver. The MR-specific antagonists also down-regulated the expression of G6Pase, while the specific agonist enhanced G6Pase expression. These observations, for the first time, revealed a novel role for MR and its ligands in the regulation of de novo glucose synthesis in hepatocytes. It also suggests the potential of liver-specific MR modulation for the treatment of hyperglycemia.
Collapse
Affiliation(s)
- Guohong Liu
- Immusol, Inc., 10790 Roselle Street, San Diego, CA 92121, USA
| | | | | | | | | | | |
Collapse
|
11
|
Liu G, Wong-Staal F, Li QX. Recent development of RNAi in drug target discovery and validation. DRUG DISCOVERY TODAY. TECHNOLOGIES 2006; 3:293-300. [PMID: 24980531 DOI: 10.1016/j.ddtec.2006.09.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
This article reviews the recent development in two areas of RNAi technology that could potentially shorten the otherwise long process of drug development. First, the combinatorial gene silencing built on the RNAi library, particularly the coming of age of 'RNAi gene' libraries, by overcoming numerous technical hurdles and also increasing understanding of miRNA biogenesis, is gradually establishing more effective approaches to identifying drug targets. Second, regulated RNAi gene expression provides tools for in vivo target validation for both on-target efficacy and potential on-target toxicity.:
Collapse
Affiliation(s)
- Guohong Liu
- Immusol Inc., 10790 Roselle Street, San Diego, CA 92121, United States
| | | | - Qi-Xiang Li
- Immusol Inc., 10790 Roselle Street, San Diego, CA 92121, United States.
| |
Collapse
|